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The lung's regenerative capacity resides within long-lived stem cells that can divide, self-renew, and differentiate to repair injured tissue or cell loss and maintain normal homeostasis. The ability to enhance endogenous stem cell capacity to regenerate lung tissue is the key to the treatment of a multitude of debilitating lung diseases such as bronchopulmonary dysplasia (BPD), idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, pulmonary arterial hypertension (PAH), and other acute and chronic ailments of the lung. The challenge lies in identifying the progenitors of a tissue and, in the case of the lung, understanding the complex interactions lung progenitors have with the unique environment of an air-liquid interphase, proximal and distal airways, the intricate vascular tree, and the innate immune response. Indeed, many different lung stem/progenitor cells have been described, and their identity and role in lung regeneration continue to be debated.
In the last decade, endothelial progenitor cells (EPCs) have been isolated from the lungs of animals and shown to have vasculogenic activity. Vasculogenesis was thought to occur only in the yolk sac of the developing embryo but this dogma was challenged in 1997 by Asahara and coworkers 1 who first reported the isolation and characterization of putative endothelial progenitor cells from human peripheral blood, showing they can differentiate into mature endothelial cells and be incorporated in the vessels of animal models of disease. Lung vascular development is closely linked with and may drive lung growth and airway development through the release of endothelial derived angiogenic factors that induce proliferation of epithelial progenitor cells to support lung alveolization. 2 Hence, lung EPCs may play a critical role not only in normal lung development but also in lung injury and repair to restore endothelial cell function and maintain homeostasis. By extension, inability of lung EPCs to maintain lung vascular integrity and repair endothelial cell dysfunction would allow injury to evolve and lead tem/progenitor cells have been described, and their identity and role in lung reg ge e ener e e a at tio io ion n n continue to be debated.
I In In t t the he he las st t t d de decade, endothelial progenitor r r c ce el lls (EPCs) have ve ve bee ee en n n is i olated from the lungs of f a a an nimals and d s sho ho hown wn to o o ha ha have v ve v vas as scu cu culo loge ge enic ac c ctivi ity y y. Va Va Vasc scu ul u o og oge en ne e esis is w w wa as t tho ho houg ught ht ht t to o o oc occu cu cur r on on onl ly n n t t the he he y y yol olk k sa sa sac c o of f t t the he d d dev ev vel elop p pin ing g g em em embr br ryo yo yo b b bu u ut th th this is do og ogma ma ma w w was as c c cha ha all l len en enge ge ed d in in 1 1 199 99 997 7 by by by A Asa saha ha h ra ra a a a and n coworkers 1 1 1 w who ho ho f f fir ir irst st s r r rep ep por r rte te t d d d th h he e e is is sol o o at at atio io ion n n an an and d d ch ch har ar arac ac a te e eri ri r za za zati ti tion on on o o of pu pu puta ta tati ti tive ve ve e end nd ndot ot othe he heli li lial a to disease. population of putative EPCs has been isolated from peripheral blood that adheres to collagen, is highly proliferative, and generates colonies within 14-21 days ("late out-growth" EPCs). 3, 4 It is these endothelial colony-forming cells (ECFCs) rather than the "early out-growth,"
hematopoietic-like, angiogenic progenitors that form chimeric vessels in in vivo models of angiogenesis. Both EPC types have been widely investigated as biomarkers of human disease and tested as therapeutic agents in preclinical models.
The early-outgrowth angiogenic EPCs have been reported to correlate inversely with disease in some studies, but the number and vasculogenic potential of ECFCs may be the strongest biomarker of endothelial dysfunction in pulmonary and systemic vascular disease.
Dysfunction of ECFCs is linked to many pathological states such as diabetes or preeclampsia.
ECFC dysfunction has been reported in infants of diabetic and pre-ecclamptic mothers as well as in low birth weight infants, and may underlie intrauterine growth restriction. 5 In diseases of the lung, ECFC dysfunction has been proposed to play a pathogenic role in patients with familial capacity and exhibit macrophage-like phagocytic activity. Unlike these cells, an n al alte te t rn n nat at ativ iv ive e e population of putative EPCs has been isolated from peripheral blood that adheres to collagen, is hi igh gh ghly ly ly p p pro ro oli li life fe ferati ti ive ve ve, , and generates colonies withi hi hin n 1 14-21 days ("l lat a a e ou ou ut-t-t-gr g owth" EPCs). 3, 4 It is h h hes s se e endothel lia ial l l c c colo lony ny y f -f -for o ormi mi ming ng c c ce el ells ls ( (E ECF F FC C Cs) r ra at th her r r t th ha han n n th th he e " "e "ear arly ly o ou u ut-g -g gro ro owt wth, h, h," " " he hema ma mato to topo po poie ie eti ti tic-c-li like ke ke, , , an an ngi gi iog ogen n nic ic p p pro ro rog ge gen ni nito to ors rs rs t t tha a at t t preterm infants. 18 The mechanism of MSC action remains elusive but is known to occur in a paracrine manner, perhaps by the release of immunomodulatory mediators, some of which are packaged in exosomes, microvesicles that carry nucleic acid material, proteins and lipids. 19 Similar microvesicles may be the carriers of ECFC action reported in the current study, potentially in cooperation with other mediators which ultimately act on the immune system to dampen inflammation, cell injury, and apoptosis, or restore the function of endogenous progenitor cells by enhancing their ability to proliferate and differentiate in order to repair the lung. The present study provides support for this mechanism of repair, and builds on previous work implicating vasculogenesis as a critical partner to lung growth.
For their ultimate use in the treatment of vascular diseases including BPD, a great deal needs to be learned about the biology of ECFCs in both normal and diseased states where accumulating literature suggests there is ECFC dysfunction. This attribute of ECFCs is a drawback to using autologous cells to regenerate the injured vasculature. Heterologous ECFCs ecently a phase I clinical trial of stored cord blood-derived MSCs was reported d f f for or B BPD PD PD i i in n n preterm infants. 18 The mechanism of MSC action remains elusive but is known to occur in a pa ara ra acr cr rin in ine e ma ma m n n nner er r, , p perhaps by the release of imm m mun un u o omodulatory me m m di iat at ato or ors, some of which are pack ck kaged in ex exo os so om mes es s, mi mi mic cr crov ov oves esic ic cle le es s th tha at car arr r ry n nuc uc clei ic ic a aci ci id d ma mate teri rial al r , pr prot otei ei eins n ns a and nd nd l l lip ipid i i s s. s. 19 19 19 Si Sim mi mila la lar r r mi micr cr cro ov oves es sic c cle les s m ma may y be be e t the he he c c ca ar arri ri ier er rs s s of of of E E ECF CF CFC C ac act tion on on r r rep ep por or o t te ted d d in in in t t the he e c cur ur urre re ent nt s s stu tu tudy dy y, f potentially in n c c coo oo o pe pe pera ra r ti ti t on o o w w wit it ith h ot ot othe he her r r me me medi di diat at ator or ors s wh wh whic ic ch h ul ul ulti ti t ma ma mate te ely ly ly ac c ct t t on on on t t the he he i imm mm mmun un une e e sy sy s stem to will induce an immune response and hence immunosuppressive therapy would be required. This is an exciting time in the field of regenerative medicine where the study of stem cell biology is exploding in parallel with intervention studies in preclinical models and in human trials to treat a wide spectrum of otherwise incurable diseases. At the same time, extreme caution must be exercised to avoid causing harm in the long run given the potential tumorigenic property of stem cell therapy and its particular relevance to the human newborn infant whose immune system is not fully developed. This requires the careful design of long-term follow-up studies to evaluate for such potential adverse complications. The authors in the present study should be commended for evaluating the long-term outcome of the treated animals, and it is encouraging to see that none of the treated animals developed tumors at 10-month follow-up. A better understanding of stem cell mechanism of action is critically-important and should be aggressively pursued as we carefully advance forward with clinical testing in humans.
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isk of adverse consequences.
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